Ali Moradi

Semmelweis University, Hungary

Title: Myocarditis Induced by Immune Checkpoint Inhibitors

Abstract

An immune checkpoint inhibitor (ICI) is one of these antitumor medications. ICIs, which are immune therapies, enhance the immune system's capacity to fight cancer cells. Based on the receptors that they inhibit, such as PD-1, PD-L1, and CTLA-4, ICIs are subdivided. Although this class of drugs is extremely beneficial for cancer patients, their adverse effects can be fatal. Immune-related adverse effects (irAEs) may have an impact on a variety of organs, such as the cardiovascular system. These cardiotoxic irAEs can occur at a rate of up to 1% and can be fatal. Myocarditis is the most prevalent of all cardiotoxicities. The purpose of this systematic review is to assess the seriousness of myocarditis, the most prevalent cardiotoxicity of ICIs, and the importance of screening. This study shows that although the risk of myocarditis in ICI therapy is low and the majority of cases are asymptomatic or mild, some cases can be deadly and disastrous, and physicians should be aware that if myocarditis is suspected based on clinical symptoms, troponin, electrocardiogram, and echocardiogram, treatment should be initiated accordingly.

Biography

TBA!!!

4th International Conference on Oncology Research and Treatment

Ali Moradi

Title: Myocarditis Induced by Immune Checkpoint Inhibitors

Abstract

Biography

Organization Location

Mail us at

Our Social Presence

Call us at